Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 31 AL 45

Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Echeverria V, Yarkov A, Aliev G.

Prog Neurobiol. 2016 Sep;144:142-57. doi: 10.1016/j.pneurobio.2016.01.002. Epub 2016 Jan 12.

Neuroprotective Role of Nanoparticles Against Alzheimer's Disease

Obulesu M, Jhansilakshmi M.

Curr Drug Metab. 2016;17(2):142-9. doi: 10.2174/138920021702160114160341.

Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products

Awasthi M, Singh S, Pandey VP, Dwivedi UN.

J Neurol Sci. 2016 Feb 15;361:256-71. doi: 10.1016/j.jns.2016.01.008. Epub 2016 Jan 8.

Recent progress on the role of GABAergic neurotransmission in the pathogenesis of Alzheimer's disease

Abbas G, Mahmood W, Kabir N.

Rev Neurosci. 2016 Jun 1;27(4):449-55. doi: 10.1515/revneuro-2015-0062.

Alzheimer's disease: Targeting the Cholinergic System

Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM.

Curr Neuropharmacol. 2016;14(1):101-15. doi: 10.2174/1570159x13666150716165726.

[Immunotherapy for Alzheimer's disease]

Falkentoft AC, Hasselbalch SG.

Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.

Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease

Pachima YI, Zhou LY, Lei P, Gozes I.

J Mol Neurosci. 2016 Feb;58(2):145-52. doi: 10.1007/s12031-016-0715-x.

Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium

Seripa D, Solfrizzi V, Imbimbo BP, Daniele A, Santamato A, Lozupone M, Zuliani G, Greco A, Logroscino G, Panza F.

Expert Rev Neurother. 2016;16(3):259-77. doi: 10.1586/14737175.2016.1140039.

Glial Cells - The Key Elements of Alzheimer´s Disease

Dzamba D, Harantova L, Butenko O, Anderova M.

Curr Alzheimer Res. 2016;13(8):894-911. doi: 10.2174/1567205013666160129095924.

BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease

Barão S, Moechars D, Lichtenthaler SF, De Strooper B.

Trends Neurosci. 2016 Mar;39(3):158-169. doi: 10.1016/j.tins.2016.01.003. Epub 2016 Jan 30.

Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease

Orhan IE, Senol FS.

Curr Top Med Chem. 2016;16(17):1889-96. doi: 10.2174/1568026616666160204121832.

Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease

Braidy N, Jugder BE, Poljak A, Jayasena T, Mansour H, Nabavi SM, Sachdev P, Grant R.

Curr Top Med Chem. 2016;16(17):1951-60. doi: 10.2174/1568026616666160204121431.

Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing

Hodes RJ, Buckholtz N.

Expert Opin Ther Targets. 2016;20(4):389-91. doi: 10.1517/14728222.2016.1135132. Epub 2016 Feb 7.

Promising Therapies for Alzheimer's Disease

Confaloni A, Tosto G, Tata AM.

Curr Pharm Des. 2016;22(14):2050-6. doi: 10.2174/1381612822666160215154218.

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A.

Neural Plast. 2016;2016:8501693. doi: 10.1155/2016/8501693. Epub 2016 Jan 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias